[Nivolumab联合化疗新辅助治疗PD-L1表达≥1的NSCLC]。

{"title":"[Nivolumab联合化疗新辅助治疗PD-L1表达≥1的NSCLC]。","authors":"Romuald Crenier , Boris Duchemann","doi":"10.1016/j.bulcan.2024.08.012","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"111 11","pages":"Pages 1003-1004"},"PeriodicalIF":1.1000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Nivolumab en association à une chimiothérapie en néoadjuvant dans les CBNPC avec expression de PD-L1 ≥ 1 %\",\"authors\":\"Romuald Crenier , Boris Duchemann\",\"doi\":\"10.1016/j.bulcan.2024.08.012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":9365,\"journal\":{\"name\":\"Bulletin Du Cancer\",\"volume\":\"111 11\",\"pages\":\"Pages 1003-1004\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bulletin Du Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0007455124003096\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin Du Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0007455124003096","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}